RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Yes, but that's only true if there are no other events foreseeable in that hypothetical 6-9 months that you mention. In Cortex's case, there are two such events that could preclude the necessity of a PIPE: SA data in May, ADHD data in December (the latter would fall beyond 6 months, obviously).

The anticipation of those events, paid for by upfront money, mean that a PIPE would not necessarily be expected, and thus would not be priced into the valuation in the same way.

NeuroInvestment